Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential

Proprotein convertase subtilisin kexin 9 (PCSK-9)-targeting therapy has arisen as a new line for the treatment of hyperlipidemia. Inclisiran is a double-stranded small RNA molecule that works by blocking the transcription of PCSK-9, leading to a reduction of PCSK9 levels in the hepatocytes, resultin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosmas, Constantine E, Muñoz Estrella, Alba, Skavdis, Andreas, Peña Genao, Edilberto, Martinez, Ian, Guzman, Eliscer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604242/
https://www.ncbi.nlm.nih.gov/pubmed/33149595
http://dx.doi.org/10.2147/TCRM.S230592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604242/
https://www.ncbi.nlm.nih.gov/pubmed/33149595
http://dx.doi.org/10.2147/TCRM.S230592

Ejemplares similares